{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-018537","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.551263+00:00","generated_at":"2026-06-18T08:39:20.900924+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jasper Therapeutics FY2022 net loss $37.7M; expands briquilimab to chronic urticaria, raises $101.4M","bullets":["FY2022 net loss $37.7M vs $30.6M in 2021; R&D $34.6M, G&A $16.6M.","Cash $38.3M at Dec 31; raised $101.4M net in Jan 2023; expects funding through 2024.","Expanding briquilimab to chronic spontaneous urticaria; 12/12 AML engraftment, 8/12 relapse-free at 1yr.","Appointed Vishal Kapoor to board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-018537","json":"https://secwatch.observer/filing/0001213900-23-018537.json","markdown":"https://secwatch.observer/filing/0001213900-23-018537.md","text":"https://secwatch.observer/filing/0001213900-23-018537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023018537/0001213900-23-018537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023018537/ea174835-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:39:20.900924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7b7a88482b38747deb522d7690b1bca849fe49e","claim":"Jasper Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: net income Net loss was $37.7 million.","evidence_excerpt":"Jasper Therapeutics, Inc. issued a press release reporting its financial results for the fiscal year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023018537/0001213900-23-018537-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $37.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}